Biochemical markers for bone turnover in osteoporosis
Institute for Clinical Systems Improvement
Record ID 32003000536
English
Authors' objectives:
This review aims to assess the available evidence on the use of biochemical markers for bone turnover measurement in osteoporosis.
Authors' recommendations:
With regard to the use of biochemical markers of bone turnover in osteoporosis, the ICSI Technology Assessment Committee finds the following:
The assessment of serum and urine biochemical markers of bone turnover is safe and minimally invasive.
While there is some population based evidence that increased values for biochemical markers are associated with increased fracture risk and that uncoupling of the bone formation/resorption mechanism is greater in fracture cases, it is not possible to predict an individuals fracture risk from biochemical marker measurements. A combination of bone mineral density and biochemical marker measurements may be of greater value but the data are inconclusive. (Conclusion Grade II)
Although population trends have been observed, biochemical markers do not have adequate sensitivity and specificity to predict osteoporosis in individual, untreated patients. The diagnosis of osteoporosis is based on a reduced BMD and/or the presence of fragility fractures. (Conclusion Grade II)
Several biochemical markers are responsive to various therapeutic options. However, there is no conclusive evidence that biochemical markers may be used to assist in selecting the type of therapy or to predict the amplitude of the BMD response for an individual patient. (Conclusion Grade II)
Although biochemical markers have the potential to be used to motivate individuals to maintain a therapy program, there are no studies of the use of biochemical markers for this purpose.
Authors' methods:
Review
Details
Project Status:
Completed
URL for project:
http://www.icsi.org/index.asp
Year Published:
2001
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Biomarkers
- Bone Remodeling
- Osteoporosis
Contact
Organisation Name:
Institute for Clinical Systems Improvement
Contact Address:
8009 34th Avenue South, Suite 1200, Bloomington, MN, USA. Tel: +1 952 814 7060; Fax: +1 952 858 9675
Contact Name:
icsi.info@icsi.org
Contact Email:
icsi.info@icsi.org
Copyright:
Institute for Clinical Systems Improvement (ICSI)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.